We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Genomics Approach Links ABO Blood Type to Inflammatory and Cardiovascular Diseases

By LabMedica International staff writers
Posted on 07 Sep 2021
Print article
Image: Blood type is determined, in part, by the ABO blood group antigens present on red blood cells (erythrocytes) (Photo courtesy of Wikimedia Commons)
Image: Blood type is determined, in part, by the ABO blood group antigens present on red blood cells (erythrocytes) (Photo courtesy of Wikimedia Commons)
A genomics approach that supplements classical blood typing procedures connects blood type phenotype to a large set of common inflammatory and cardiovascular diseases.

Previous studies have primarily focused on identifying associations between ABO blood groups and diseases risk. To expand this work, investigators at the University of Uppsala (Sweden) sought to test for association between ABO genotypes (OO, OA, AA; OB, BB, and AB) and a large set of common inflammatory and cardiovascular diseases as well as disease-related protein biomarkers.

For this work, materials were obtained from The UK Biobank, which is a prospective observational study of approximately 500,000 volunteers aged 40 to 69 years who were recruited from 22 sites across the United Kingdom between 2006 and 2010.

The investigators tested for association by conducting a likelihood ratio test, examining whether ABO status contributed significantly to the risk for 24 diseases, and 438 plasma proteins.

Results confirmed previous findings of a strong association between ABO and cardiovascular disease, identified associations for both type I and type II diabetes, and provided additional evidence of significant differences between heterozygous and homozygous allele carriers for pulmonary embolism, deep vein thrombosis, but also for von Willebrand factor levels. In addition, the results indicated an additive effect between genotypes, even between the two most common A subgroups, A1 and A2. The investigators also found that ABO contributed significantly to 39 plasma proteins, of which 23 had never been linked to the ABO locus before.

"There is a large difference for the risk for blood clots, depending on if someone has one or two genetic variants of the blood groups A, AB, or B. Simply put, there is twice the risk of suffering from blood clots if you have two variants of A or B rather than just one," said first author Julia Höglund, a doctoral student in immunology, genetics, and pathology at Uppsala University. "This is not detected in a regular blood test since both A and B mask the O gene. A person's genetic variants play a big role in the risk for cardiovascular diseases. If this was the standard method used with patients, it would significantly improve the ability to find high-risk patients. Our findings show that by making it standard to determine the patient's blood group and the blood group's genetics, we would be able to discover and begin treating diseases at an early stage, which can prevent or delay serious complications."

The ABO genomics study was published in the July 30, 2021, online edition of the American Journal of Hematology.

Related Links:
Uppsala University

Gold Supplier
Proficiency Assessment Software
CellaVision Proficiency Software
Gold Supplier
Liquid Handling Workstation
AdvanSure E3 SYSTEM
Silver Supplier
Automated Nucleic Acid Extractor
Gold Supplier
Rapid PCR Diagnostic System
Accula System

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.